Co-delivery of Tacrolimus and Thymoquinone topically by Nanostructured lipid carriers gel for enhanced efficacy against imiquimod-induced psoriasis in Balb/c mice DOI Creative Commons
Meraj Alam, Md. Rizwanullah, Shahnawaz Ahmad

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: June 3, 2024

Abstract The primary objective of this current investigation is to evaluate the antipsoriatic potential a novel nanogel delivery system that co-encapsulates tacrolimus and thymoquinone within nanostructured lipid carriers (NLCs). Therefore, TAC-THQ-NLCs-gel was formulated by emulsification solvent-evaporation technique evaluated for their in improving skin permeation, bioavailability, safety, therapeutic efficacy imiquimod-induced psoriasis mice plaque model. ex-vivo permeation study shows 2.51- 2.12-folds higher as compared TAC-THQ-suspension-gel, also enhancement mechanism NLCs gel confirmed using FTIR DSC. Further retention 2.87- 2.36-fold improvement drug free formulation. Further, dermatokinetic 2.78 2.37 folds Cmax 2.93- 2.40-fold AUC (area under curve) TAC THQ respectively drugs gel. results in-vivo compliance suggested fabricated safe delivery. Furthermore, TAC-THQ-NLCS-gel represented much better amelioration Balb/c mice, with cumulative PASI score reduction 83.80% 57.14% after end treatment. In addition, insignificant changes histology skin, spleen, liver further confirm safety developed TAC-THQ-NLCs-gel. Based on these observations, it can be inferred holds promise combined treatment approach managing topically.

Language: Английский

Multicenter proteome-wide Mendelian randomization study identifies causal plasma proteins in melanoma and non-melanoma skin cancers DOI Creative Commons
Yajia Li, Qiangxiang Li, Ziqin Cao

et al.

Communications Biology, Journal Year: 2024, Volume and Issue: 7(1)

Published: July 13, 2024

Abstract This study addresses the diagnostic and therapeutic challenges in malignant melanoma (MM) non-melanoma skin cancers (NMSC). We aim to identify circulating proteins causally linked MM NMSC traits using a multicenter Mendelian randomization (MR) framework. utilized large-scale cis-MR estimate impact of numerous plasma on MM, NMSC, squamous cell carcinoma (SCC), basal (BCC). To ensure robustness, additional analyses like MR Steiger Bayesian colocalization are conducted, followed by replication through meta-analytical methods. The associations between identified outcomes also validated at tissue level Transcriptome-Wide Association Study Furthermore, protein-protein interaction analysis is conducted explore relationship existing cancer medication targets. has 13 with BCC, 2 SCC, 1 MM. Specifically, ASIP KRT5 associated potentially targeting CTSS TNFSF8 as promising druggability candidates for BCC. multidimensional approach nominates ASIP, KRT5, CTSS, potential targets cancers.

Language: Английский

Citations

1
Enhanced Skin Penetration and Efficacy: First and Second Generation Lipoidal Nanocarriers in Skin Cancer Therapy DOI
Palak Sharma, Shreya Kaul, Neha Jain

et al.

AAPS PharmSciTech, Journal Year: 2024, Volume and Issue: 25(6)

Published: July 24, 2024

Language: Английский

Citations

1
Co-delivery of Paclitaxel and Cannabidiol in Lipid Nanoparticles Enhances Cytotoxicity Against Melanoma Cells DOI Open Access
Fabíola Vieira de Carvalho, Gabriela Gerônimo, Ludmilla David de Moura

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 18, 2024

ABSTRACT Although chemotherapy regimens are well-established in clinical practice, chemoresistance and adverse side effects pose significant obstacles cancer treatment. Paclitaxel (PTX), a widely used chemotherapeutic agent, faces formulation challenges due to its poor solubility permeability. Research suggests that the phytochemical Cannabidiol (CBD) holds potential not only targeting cells but also alleviating pain nausea, thereby improving quality of life for patients. However, CBD’s application is limited by solubility, low bioavailability, susceptibility oxidation. Nanostructured lipid carriers (NLCs) represent promising drug delivery system hydrophobic compounds like PTX CBD allows their co-encapsulation. Nonetheless, achieving stable requires identifying suitable preparation methods excipients. The aim this study was develop optimize an NLC co-encapsulation CBD. Using factorial design, optimized obtained with homogeneous particle sizes (200 nm), negative zeta potentials (−17 mV), concentration 10 13 particles/mL, spherical morphology (TEM images), core crystallinity (as confirmed XRD). To evaluate therapeutic combination, cell viability assays were conducted on murine melanoma (B16-F10) at different exposure times (24 48 hours). NLC-CBD-PTX significantly reduced time- concentration-dependent manner, demonstrating least 75% greater activity 24 hours compared each individually whether free (PTX, CBD) or encapsulated (NLC-PTX, NLC-CBD). This indicates synergistic effect drugs cytotoxicity. In conclusion, innovative pharmaceutical co-encapsulating validated, showing enhance antitumor efficacy, overcome chemoresistance, reduce effects, broaden applications. resulting NLCs exhibited favorable physicochemical properties, supporting suitability various routes administration.

Language: Английский

Citations

1
Advancements in Ischemic Stroke Management: Transition from Traditional to Nanotechnological Approaches DOI

Mohammad Adil,

Umme Jiba,

Afshan Khan

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: unknown, P. 106318 - 106318

Published: Oct. 1, 2024

Language: Английский

Citations

1
Co-delivery of Tacrolimus and Thymoquinone topically by Nanostructured lipid carriers gel for enhanced efficacy against imiquimod-induced psoriasis in Balb/c mice DOI Creative Commons
Meraj Alam, Md. Rizwanullah, Shahnawaz Ahmad

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: June 3, 2024

Abstract The primary objective of this current investigation is to evaluate the antipsoriatic potential a novel nanogel delivery system that co-encapsulates tacrolimus and thymoquinone within nanostructured lipid carriers (NLCs). Therefore, TAC-THQ-NLCs-gel was formulated by emulsification solvent-evaporation technique evaluated for their in improving skin permeation, bioavailability, safety, therapeutic efficacy imiquimod-induced psoriasis mice plaque model. ex-vivo permeation study shows 2.51- 2.12-folds higher as compared TAC-THQ-suspension-gel, also enhancement mechanism NLCs gel confirmed using FTIR DSC. Further retention 2.87- 2.36-fold improvement drug free formulation. Further, dermatokinetic 2.78 2.37 folds Cmax 2.93- 2.40-fold AUC (area under curve) TAC THQ respectively drugs gel. results in-vivo compliance suggested fabricated safe delivery. Furthermore, TAC-THQ-NLCS-gel represented much better amelioration Balb/c mice, with cumulative PASI score reduction 83.80% 57.14% after end treatment. In addition, insignificant changes histology skin, spleen, liver further confirm safety developed TAC-THQ-NLCs-gel. Based on these observations, it can be inferred holds promise combined treatment approach managing topically.

Language: Английский

Citations

0